Medivation (MDVN) Higher on Positive Data from J&J's Zytiga
Tweet
Share
E-mailGet Alerts MDVN Hot Sheet
Join SI Premium – FREE
Medivation, Inc. (Nasdaq: MDVN) moves higher on positive positive prostate cancer results from Johnson & Johnson's (NYSE: JNJ) Zytiga. The trial was stopped early due to positive efficacy.
Shares of Medivation are up 4.5 percent.
Shares of Medivation are up 4.5 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Trump admin taps former JPMorgan Chase exec Matt Zames to advise social security agency - CNBC
- DOJ, TikTok settle for $400m in children's privacy suit - Axios
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
